Drug Description
One vial contains 400 Units* of velaglucerase alfa.After reconstitution, one ml of the solution contains 100 Units of velaglucerase alfa.*An enzyme unit is defined as the amount of enzyme that is required to convert one micromole of pnitrophenyl ?-D-glucopyranoside to p-nitrophenol per minute at 37ºC.Velaglucerase alfa is produced in an HT-1080 human fibroblast cell line by recombinant DNA technology.Excipients:One vial contains 12.15 mg sodium.
Presentation
Powder for solution for infusionWhite to off-white powder
Indications
VPRIV is indicated for long-term enzyme replacement therapy (ERT) in patients with type 1 Gaucher disease.
Adult Dosage
VPRIV treatment should be supervised by a physician experienced in the management of patients with Gaucher disease. Home administration under the supervision of a healthcare professional may be considered only for patients who have received at least three infusions and were tolerating their infusions well.
Posology
